Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Michael J MorrisGlenn HellerDavid W HillmanOlivia BobekCharles RyanEmmanuel S AntonarakisAlan H BryceOlwen HahnHimisha BeltranAndrew J ArmstrongLawrence SchwartzLionel D LewisJan H BeumerBrooke LangevinEric C McGaryPaul T MehanAmir GoldkornBruce J RothHan XiaoColleen WattMary-Ellen TaplinSusan HalabiEric J SmallPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The addition of AAP to enzalutamide for first-line treatment of mCRPC was not associated with a statistically significant benefit in OS. Drug-drug interactions between the two agents resulting in increased abiraterone clearance may partly account for this result, although these interactions did not prevent the combination regimen from having more nonhematologic toxicity.